Sino-US artificial intelligence (AI) firm XtalPi Inc. has partnered with China’s Chia Tai Tianqing to reach the Phase II milestone in their small molecule cancer drug research and development (R&D) program. The collaboration leveraged Chia Tai Tianqing’s in-house innovative drug innovation platform and XtalPi’s AI drug discovery platform to achieve the Pre-PCC (preclinical candidate) milestone efficiently and smoothly.
Background of the Partnership
The two companies first established their partnership at the beginning of 2022 with the goal of developing best-in-class small molecules. The first milestone was achieved ahead of schedule, demonstrating a 50% time saving compared to traditional methods.
Significance of the Milestone
This achievement highlights the effectiveness of combining AI-driven drug discovery with innovative drug development platforms. The partnership between XtalPi and Chia Tai Tianqing is poised to accelerate the development of new cancer therapies, potentially reducing the time and cost associated with bringing innovative drugs to market.
Future Prospects
The successful attainment of the Phase II milestone sets the stage for further advancements in the cancer drug development program. Both companies are committed to continuing their collaboration, leveraging their respective strengths to drive innovation and improve patient outcomes in cancer treatment.-Fineline Info & Tech
